Inhibitors of histone deacetylase

1. A compound of formula (2)

or a pharmaceutically acceptable salt thereof, wherein

Cy 2 is aryl or heteroaryl, each of which is optionally substituted and wherein each of aryl and heteroaryl is optionally fused to one or more aryl or heteroaryl rings, or to one or more saturated or partially unsaturated cycloalkyl or heterocyclic rings, each of which rings is optionally substituted;

X is selected from the group consisting of: a covalent bond, C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(CO)—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(NR 7 )—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(S)—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(O)—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(SO)—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(SO 2 )—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(NH)—(CO)—C 0 -C 4 -hydrocarbyl, C 0 -C 4 -hydrocarbyl-(CO)—(NH)—C 0 -C 4 -hydrocarbyl, —NH—CO—NH—, —NH—CS—NH—, —O—CO—O—, —O—CS—O—, —NH—C(NH)—NH—, —S(O) 2 —N(R 7 )—, —N(R 7 )—S(O) 2 —, —NH—C(O)—O—, and —O—C(O)—NH—,

wherein R 7 is selected from the group consisting of hydrogen, C 1 -C 5 -alkyl, aryl, aralkyl, acyl, heterocyclyl, heteroaryl, SO 2 -alkyl, SO 2 -aryl, CO-alkyl, CO-aryl, CO—NH-alkyl, CO—NH-aryl, CO—O-alkyl and CO—O-aryl, each of which is optionally substituted,

n is 0 to 4,

Y is N or CH, and

T is NH 2 or OH.

2. A compound according to claim 1 having S stereochemistry at C-3 position of the ring

3. A compound according to claim 1 having R stereochemistry at C-3 position of the ring

4. A compound according to claim 1 , selected from the group consisting of:

N-(2-Amino-phenyl)-4-[3-(pyridin-3-ylamino)-pyrrolidin-1-yl]-benzamide;

(S)-N-(2-Aminophenyl)-4-(3-(pyridin-3-ylamino)pyrrolidin-1-yl)benzamide;

(R)-N-(2-aminophenyl)-4-(3-(pyridin-3-ylamino)pyrrolidin-1-yl)benzamide;

(S)-N-(2-Aminophenyl)-4-(3-(pyridin-3-yloxy)pyrrolidin-1-yl)benzamide

(R)-N-(2-Aminophenyl)-4-(3-(pyridin-3-yloxy)pyrrolidin-1-yl)benzamide;

(S)-N-(1-(4-(2-Aminophenyl carbamoyl)phenyl)pyrrolidin-3-yl)nicotinamide;

(S)-N-(2-Aminophenyl)-4-(3-(pyridin-2-ylthio)pyrrolidin-1-yl)benzamide; and

N-(2-Aminophenyl)-4-((S)-3-((S)-pyridin-2-ylsulfinyl)pyrrolidin-1-yl)benzamide.

5. A composition comprising a mixture of enantiomers of compounds of claim 1 .

6. The composition of claim 5 wherein the mixture is racemic.

7. The composition of claim 5 wherein the mixture is enantiomerically enriched.

8. A composition comprising one or more compounds according to any one of claims 1 - 4 and a pharmaceutically acceptable carrier.